Your diagnosis of non-small cell lung cancer will be confirmed through tissue analysis. This cancer must be at an advanced stage that cannot be surgically removed or has spread to other parts of the body.

A test will be performed on your tumor tissue to measure the level of a protein called PD-L1. Your tumor must have at least 1% of cells expressing this protein to participate in this study.

Tissue samples from your tumor will be collected for laboratory analysis. This can be either previously collected tissue, preferably from within the last 12 months, or a new tissue sample obtained through a biopsy procedure if medically appropriate.

Your previous cancer treatments will be reviewed. You must have received platinum-based chemotherapy (a type of cancer treatment using platinum-containing drugs) and treatment with a PD-L1 antibody (a type of immunotherapy), and your cancer must have progressed or returned after these treatments.

You will be randomly assigned to one of two treatment groups. This means that neither you nor your doctor will choose which treatment you receive.

One group will receive the investigational medicine called PF-08046054, which is an antibody attached to a cancer-fighting drug.

The other group will receive docetaxel, a standard chemotherapy medication used for lung cancer treatment.

If you are assigned to receive PF-08046054, the medication will be administered through an intravenous infusion, which means it will be delivered directly into your vein over a period of time.

If you are assigned to receive docetaxel, this medication will also be given through an intravenous infusion into your vein.

The specific dosage, frequency of administration, and duration of treatment will be determined according to the study protocol and your individual medical situation.

You will receive repeated cycles of treatment as long as the treatment is providing benefit and you are not experiencing unacceptable side effects.

Throughout the study, your cancer will be monitored through imaging scans to assess whether the tumor is shrinking, staying the same, or growing.

Blood samples will be collected at specific times during treatment. If you are receiving PF-08046054, these samples will measure the levels of the medication and its components in your blood, including measurements at the end of each infusion and before the next dose.

You will be monitored for any side effects or adverse reactions to the treatment. All side effects will be recorded, including their type, severity, and relationship to the study medication.

If you are receiving PF-08046054, your immune response to the medication will be assessed by testing whether your body has developed antibodies against the treatment.

You will be asked to complete questionnaires at regular intervals to assess your quality of life and overall well-being.

These questionnaires will ask about your general health status, your ability to perform daily activities, and your physical functioning.

You will also answer questions specifically related to lung cancer symptoms, such as difficulty breathing, cough, and chest pain.

The questionnaires will help assess any changes in your symptoms and quality of life during the treatment period.

Your treatment will continue as long as it is effective and you are tolerating it without serious side effects.

Your doctor will regularly evaluate your response to treatment based on imaging scans and clinical assessments.

The duration of your participation in the study will depend on how your cancer responds to treatment and your overall health status.

Long-term survival information will be collected as part of the study to compare the effectiveness of the two treatments.